Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Ventyx Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATA FROM THE RECENT PHASE 2 STUDY POSITION VENTYX'S NLRP3 INHIBITOR VTX3232 AS A NEXT GENERATION, ORAL ANTI-INFLAMMATORY THERAPY, FOR CARDIOVASCULAR DISEASE POSITIVE TOPLINE DATA FROM PHASE 2A BIOMARKER TRIAL SUPPORT THE POTENTIAL USE OF VTX3232 AS A DISEASE-MODIFYING THERAPY FOR PATIENTS WITH PARKINSON'S DISEASE TOPLINE DATA FROM PHASE 2 STUDY OF VTX2735 IN PATIENTS WITH RECURRENT PERICARDITIS EXPECTED IN Q4 2025 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BALANCE OF $192.6M AS OF SEPTEMBER 30, 2025, EXPECTED TO FUND PLANNED OPERATIONS INTO AT LEAST H2 2026 SAN DIEGO, NOV. 06, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAY REPORTED THIRD QUARTER FINANCIAL RESULTS AND HIGHLIGHTED RECENT PIPELINE AND BUSINESS PROGRESS. I AM PROUD OF THE VENTYX TEAM FOR ACHIEVING TWO KEY MILESTONES THIS YEAR, GENERATING DATA FROM THE PHASE 2A STUDY WITH OUR CNS PENETRANT NLRP3 INHIBITOR VTX3232 IN PATIENTS WITH EARLY PARKINSON'S DISEASE AND, MORE RECENTLY, DATA FROM THE VTX3232 PHASE 2 STUDY IN PARTICIPANTS WITH OBESITY AND CARDIOVASCULAR RISK FACTORS.

VENTYX BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE PROGRESS

VTX3232 DEMONSTRATED SIGNIFICANT REDUCTIONS IN CARDIOVASCULAR RISK FACTORS, WITH ADDITIONAL BENEFITS WHEN COMBINED WITH SEMAGLUTIDE VTX3232 MONOTHERAPY ACHIEVED ~80% REDUCTION IN HSCRP WITHIN THE FIRST WEEK VTX3232 MONOTHERAPY REDUCED IL-6 LEVELS AT WEEK 12 BELOW THE THRESHOLD FOR CARDIOVASCULAR RISK OF 1.65NG/L 1 STATISTICALLY SIGNIFICANT REDUCTIONS IN LP(A) AND LIVER INFLAMMATION NO EFFECT ON WEIGHT EITHER AS A MONOTHERAPY OR AS ADD-ON TO SEMAGLUTIDE VTX3232 WAS SAFE AND WELL TOLERATED BOTH AS A MONOTHERAPY AND ADD-ON TO SEMAGLUTIDE IN THIS STUDY VENTYX TO HOLD CONFERENCE CALL AND WEBCAST 4:30PM ET ON WEDNESDAY, OCTOBER 22ND SAN DIEGO, OCT. 22, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), TODAY ANNOUNCED POSITIVE RESULTS FROM ITS PHASE 2 STUDY OF ORAL, ONCE-DAILY VTX3232 IN PATIENTS WITH OBESITY AND CARDIOVASCULAR RISK FACTORS. THE 175- PARTICIPANT STUDY EXAMINED VTX3232 VERSUS PLACEBO, ALONE OR IN COMBINATION WITH SEMAGLUTIDE, EVALUATING SAFETY AND TOLERABILITY AS THE PRIMARY ENDPOINT, AND EFFECTS ON INFLAMMATION (MEASURED BY HIGH-SENSITIVITY C-REACTIVE PROTEIN OR HSCRP) AS THE SECONDARY ENDPOINT.

VENTYX BIOSCIENCES ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF VTX3232 IN PARTICIPANTS WITH OBESITY AND CARDIOVASCULAR RISK FACTORS

SAN DIEGO, AUG. 27, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT COMPANY EXECUTIVES WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: 2025 WELLS FARGO HEALTHCARE CONFERENCE LOCATION: BOSTON, MADATE: FRIDAY, SEPTEMBER 5, 2025TIME: 11:00-11:35 AM EDT MORGAN STANLEY 23 RD ANNUAL GLOBAL HEALTHCARE CONFERENCE LOCATION: NEW YORK, NYDATE: MONDAY, SEPTEMBER 8, 2025 H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE LOCATION: NEW YORK, NYDATE: MONDAY, SEPTEMBER 8, 2025 A WEBCAST OF THE WELLS FARGO PRESENTATION WILL BE AVAILABLE IN THE INVESTORS AND NEWS SECTION OF THE VENTYX WEBSITE AT WWW.VENTYXBIO.COM.

VENTYX BIOSCIENCES TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES

THE STUDY MET ITS PRIMARY GOAL OF ESTABLISHING SAFETY AND TOLERABILITY OF VTX3232 IN PATIENTS WITH EARLY-STAGE PARKINSON'S DISEASE

VENTYX BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM ITS PHASE 2A SAFETY AND BIOMARKER TRIAL EVALUATING VTX3232 IN PATIENTS WITH EARLY-STAGE PARKINSON'S DISEASE

SAN DIEGO, MAY 28, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAYANNOUNCED THAT COMPANY EXECUTIVES WILL PARTICIPATE IN A FIRESIDE CHAT AT THE UPCOMING JEFFERIES GLOBAL HEALTHCARE CONFERENCE. EVENT: JEFFERIES GLOBAL HEALTHCARE CONFERENCE, NEW YORK FIRESIDE CHATDATE: THURSDAY, JUNE 5, 2025 TIME: 12:50-1:20 PM ET A WEBCAST OF THE EVENT WILL BE AVAILABLE IN THE INVESTORS AND NEWS SECTION OF THE VENTYX WEBSITE AT WWW.VENTYXBIO.COM.

VENTYX BIOSCIENCES TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

TOPLINE DATA FROM MULTIPLE PHASE 2 STUDIES EXPECTED THROUGHOUT 2025 Q2 READOUT FROM VTX3232 STUDY IN PATIENTS WITH EARLY PARKINSON'S DISEASE H2 READOUT FROM VTX2735 STUDY IN PATIENTS WITH RECURRENT PERICARDITIS H2 READOUT FROM VTX3232 STUDY IN PARTICIPANTS WITH OBESITY AND CARDIOMETABOLIC RISK FACTORS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BALANCE OF $228.8M AS OF MARCH 31, 2025 EXPECTED TO FUND PLANNED OPERATIONS INTO AT LEAST H2 2026 SAN DIEGO, MAY 08, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAY REPORTED FIRST QUARTER FINANCIAL RESULTS AND HIGHLIGHTED RECENT PIPELINE AND BUSINESS PROGRESS. VENTYX HAS ESTABLISHED ITSELF AS THE LEADER IN DISCOVERY AND DEVELOPMENT OF NLRP3 INHIBITORS WITH TWO NOVEL COMPOUNDS, VTX3232 AND VTX2735 PROGRESSING THROUGH PHASE 2 TRIALS IN NEURODEGENERATIVE, CARDIOVASCULAR, AND METABOLIC INDICATIONS - DISEASE STATES THOUGHT TO BE DRIVEN BY PATHOLOGIC ACTIVATION OF THE NLRP3 INFLAMMASOME, SAID RAJU MOHAN, PHD, PRESIDENT AND CHIEF EXECUTIVE OFFICER.

VENTYX BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE PROGRESS

APPOINTMENT OF SEVEN RECOGNIZED EXPERTS IS VALIDATING FOR VENTYX'S NLRP3 PROGRAM -- AD/PD 2025 PROVIDES HELPFUL INSIGHTS ON POTENTIAL NEXT STEPS IN PARKINSON'S DISEASE SAN DIEGO, APRIL 01, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF SEVEN ADDITIONAL INTERNATIONALLY-RECOGNIZED SCIENTISTS AND CLINICIANS TO ITS SCIENTIFIC ADVISORY BOARD (SAB): MO LAMKANFI, PHD, LUKE O'NEILL, PHD, TED DAWSON, MD, PHD, MARTIN POMPER, MD, PHD, ANTONIO ABBATE, MD, PHD, PAUL CREMER, MD AND DON FRAIL, PHD. THE NEW SAB MEMBERS HAVE MADE VITAL DISCOVERIES IN UNDERSTANDING THE ROLE OF THE NLRP3 INFLAMMASOME IN NEURO- AND SYSTEMIC INFLAMMATION, AND ARE AT THE FOREFRONT OF CLINICAL DEVELOPMENT IN NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASES.

VENTYX BIOSCIENCES EXPANDS SAB WITH RENOWNED NLRP3 EXPERTS AND PROMINENT NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE SPECIALISTS

TOPLINE DATA READOUTS FROM MULTIPLE PHASE 2 STUDIES EXPECTED THROUGHOUT 2025 VTX2735 IN PATIENTS WITH RECURRENT PERICARDITIS IN H2 VTX3232 IN PARTICIPANTS WITH OBESITY AND CARDIOMETABOLIC RISK FACTORS IN H2 VTX3232 BIOMARKER STUDY IN PATIENTS WITH EARLY PARKINSON'S DISEASE IN Q2 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BALANCE OF $252.9M AS OF DECEMBER 31, 2024 EXPECTED TO FUND OPERATIONS INTO AT LEAST H2 2026 SAN DIEGO, FEB. 27, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAY REPORTED FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTED RECENT PIPELINE AND BUSINESS PROGRESS. HEADING INTO 2025, VENTYX HAS ESTABLISHED ITSELF AS THE LEADER IN THE FIELD OF NLRP3 INHIBITION HAVING PROGRESSED TWO NOVEL INHIBITORS, VTX3232 AND VTX2735, INTO PHASE 2 TRIALS IN NEURODEGENERATIVE, CARDIOVASCULAR, AND METABOLIC INDICATIONS.

VENTYX BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE PROGRESS

POSTER HIGHLIGHTS ROBUST, DOSE-DEPENDENT ENDOSCOPIC RESPONSE WITH VTX958 AND REDUCTIONS IN KEY INFLAMMATORY MARKERS FULL ANALYSIS OF PHASE 2 RESULTS, INCLUDING DATA FROM THE 52-WEEK TREAT-THROUGH LTE PHASE, IS EXPECTED TO INFORM DEVELOPMENT STRATEGY AND PARTNERSHIP OPPORTUNITIES FOR VTX958 SAN DIEGO, FEB. 18, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT DATA FROM THE PHASE 2 TRIAL OF ITS TYK2 INHIBITOR VTX958 IN CROHN'S DISEASE WILL BE PRESENTED DURING THE 20TH CONGRESS OF THE EUROPEAN CROHN'S AND COLITIS ORGANISATION (ECCO) BEING HELD IN BERLIN, GERMANY FROM FEBRUARY 19-22, 2025. THE PHASE 2 DATA FOR VTX958 IN CROHN'S DISEASE REPRESENT AN IMPORTANT MILESTONE FOR TYK2 INHIBITION IN INFLAMMATORY BOWEL DISEASE, SAID RAJU MOHAN, PHD, FOUNDER AND CHIEF EXECUTIVE OFFICER.

VENTYX BIOSCIENCES ANNOUNCES PRESENTATION OF DATA FROM THE PHASE 2 TRIAL OF ALLOSTERIC TYK2 INHIBITOR VTX958 IN CROHN'S DISEASE AT ECCO 2025

SAN DIEGO, FEB. 05, 2025 (GLOBE NEWSWIRE) -- VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) (VENTYX, COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE ORAL THERAPIES FOR PATIENTS WITH AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES, TODAYANNOUNCED THAT COMPANY EXECUTIVES WILL PARTICIPATE IN THE UPCOMING OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE.

VENTYX BIOSCIENCES TO PARTICIPATE IN THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE

FIRST SUBJECTS DOSED IN A PHASE 2 TRIAL OF VTX3232 IN PARTICIPANTS WITH OBESITY AND CARDIOMETABOLIC RISK FACTORS, WITH TOPLINE DATA EXPECTED IN H2 2025

Ventyx Biosciences, Inc.

VTYX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ventyx Biosciences, Inc.

VTYX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VTYX